Abbott Laboratories $ABT Shares Sold by Perigon Wealth Management LLC

Perigon Wealth Management LLC cut its holdings in Abbott Laboratories (NYSE:ABT) by 29.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 43,168 shares of the healthcare product maker’s stock after selling 17,779 shares during the period. Perigon Wealth Management LLC’s holdings in Abbott Laboratories were worth $3,917,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Phillips Wealth Planners LLC boosted its holdings in shares of Abbott Laboratories by 5.5% during the second quarter. Phillips Wealth Planners LLC now owns 8,398 shares of the healthcare product maker’s stock worth $805,000 after purchasing an additional 438 shares during the last quarter. Trust Co. of Vermont acquired a new stake in Abbott Laboratories in the 2nd quarter worth about $17,340,000. Plato Investment Management Ltd grew its holdings in Abbott Laboratories by 0.4% in the 2nd quarter. Plato Investment Management Ltd now owns 44,606 shares of the healthcare product maker’s stock valued at $4,024,000 after buying an additional 157 shares during the period. Bell Investment Advisors Inc increased its stake in shares of Abbott Laboratories by 5.6% during the 2nd quarter. Bell Investment Advisors Inc now owns 2,300 shares of the healthcare product maker’s stock valued at $209,000 after acquiring an additional 122 shares during the last quarter. Finally, Hexagon Capital Partners LLC increased its stake in shares of Abbott Laboratories by 5.5% during the 2nd quarter. Hexagon Capital Partners LLC now owns 3,400 shares of the healthcare product maker’s stock valued at $309,000 after acquiring an additional 177 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 6th. UBS Group lowered their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketones. The device is cleared for diabetes patients age two and older and could strengthen Abbott’s Libre franchise, particularly as the company works toward integration with insulin pumps. What Does Abbott Laboratories FDA Clearance Mean for Its Diabetes Device Push?
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is intended to reduce stroke risk in patients with non-valvular atrial fibrillation and may reduce reliance on blood-thinning medication. Recent trial data reportedly met safety and effectiveness benchmarks, supporting Abbott’s structural-heart and electrophysiology businesses. Abbott Amulet 360 Receives CE Mark
• Positive Sentiment: TD Cowen analyst commentary indicated that Abbott’s stock could rise, providing an additional vote of confidence in the company’s outlook. TD Cowen Says Abbott Stock Could Rise
• Neutral Sentiment: The regulatory approvals are strategically important, but their financial benefits will depend on commercial adoption, reimbursement, competitive responses and the timing of integration with insulin-pump systems.
• Negative Sentiment: Abbott underperformed while the broader market gained. The pullback suggests that investors may be focusing on the stock’s relatively high valuation and the fact that the newly approved products are longer-term growth catalysts rather than immediate earnings drivers. Why Abbott Stock Declined as the Market Gained

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $111.46 on Friday. The firm has a fifty day moving average of $102.12 and a 200-day moving average of $100.13. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $192.87 billion, a P/E ratio of 36.07, a PEG ratio of 2.21 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the business posted $1.26 EPS. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.